Prognostic and Predictive Value of the 21-Gene Recurrence Score® for Women with Node-Positive Breast Cancer Receiving Chemotherapy

For more visit ResearchToPractice.com/5MJCBreast
CME INFORMATION

OVERVIEW OF ACTIVITY

The annual San Antonio Breast Cancer Symposium (SABCS) is unmatched in its significance with regard to the advancement of breast cancer treatment. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year where published results from a plethora of ongoing clinical trials lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across all breast cancer subtypes. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of the rapidly evolving data sets in breast cancer. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest SABCS meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for breast cancer.

LEARNING OBJECTIVE

• Identify the prognostic and predictive value of the 21-gene Recurrence Score for chemotherapy benefit in postmenopausal women with node-positive and ER-positive breast cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentation, read the commentary and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Adam M Brufsky, MD, PhD
Associate Professor of Medicine, University of Pittsburgh
Associate Director for Clinical Investigation
University of Pittsburgh Cancer Institute
Co-Director, Comprehensive Breast Cancer Center
Associate Division Chief, University of Pittsburgh
Department of Medicine, Division of Hematology/Oncology
Pittsburgh, Pennsylvania


Joseph A Sparano, MD
Professor of Medicine and Women’s Health
Albert Einstein College of Medicine
Associate Chairman, Department of Oncology
Montefiore Medical Center
Bronx, New York

Advisory Committee: Bristol-Myers Squibb Company, Genentech BioOncology, Pfizer Inc; Consulting Agreement: Eisai Inc; Paid Research: Bristol-Myers Squibb Company, Genentech BioOncology, ImClone Systems Incorporated; Speakers Bureau: GlaxoSmithKline.

EDITOR — Neil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services LLC, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram Biosciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc and Sanofi-Aventis.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS
— The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech BioOncology, Genomic Health Inc and GlaxoSmithKline.

Last review date: February 2010
Expiration date: February 2011
IN THIS ISSUE:

- **SWOG analysis** again demonstrates lack of benefit of adjuvant chemotherapy for patients with node-positive tumors and low Recurrence Scores®

- **Survey demonstrates** similar clinical practice impact of Oncotype DX for patients with node-positive tumors to that previously seen with node-negative tumors

- **Oncotype DX results from core biopsies** similar to those from excisional biopsies

The current Phase III adjuvant breast cancer research platform to a great extent was shaped by the deep passion and commitment of two legendary clinical investigators, the NSABP’s Dr Bernard Fisher and Dr Gianni Bonadonna from the Milan Cancer Institute. Bernie was actually the first person interviewed when the Breast Cancer Update audio series was launched in 1988, and not long after, I met up with the very suave Dr Bonadonna, who resembled a classic Italian movie star much more than a world-class scientist. Beginning in the late 1960s, these fiery and inspirational leaders persuaded an international audience to support clinical trials evaluating the then-heretical idea of giving chemotherapy to patients who might already be cured. Bonadonna managed to obtain support for the logical approach of adjuvant combination chemotherapy (CMF), while Bernie struggled just to study L-PAM.

At this year’s San Antonio meeting I met Dr Bonadonna’s protégé, Dr Luca Gianni, who last year at the meeting presented the NOAH study that was just published in the JCO and demonstrated Buzdar-like results of neoadjuvant chemo with a trastuzumab/anthracycline-containing regimen for locally advanced HER2-positive disease. With the excellent Italian research infrastructure developed by Dr Bonadonna and others, including Dr Umberto Veronesi, Dr Gianni has led a number of important studies of pre-op therapy, including one of the few to investigate Oncotype DX as a predictor of response to neoadjuvant chemotherapy. (As one might guess, it predicted path CRs.) At the end of our chat, Dr Gianni casually mentioned that his cooperative group (Fondazione Michelangelo) was running a trial randomizing patients with ER-positive, HER2-negative, node-positive tumors and low Recurrence Scores to hormone therapy alone or preceded by chemotherapy.

Upon hearing these words, I swallowed and asked, just to be sure: “So this is essentially a TAILORRx-like study for patients with node-positive tumors?” His answer was simply, “Yes.” Walking back to the “Marriott attached to the mall,” I ran into Dan Hayes and asked if he knew that the Italians had pulled off what the US cooperative groups had been trying to implement since Kathy Albain presented the initial 2007 San Antonio SWOG node-positive data set on Oncotype DX. It was news to Dan, who seemed frustrated by the glacier-like trial development and review process in the United States.
Meanwhile, *Lancet Oncology* had teamed up with Dr Albain, the SWOG investigators and San Antonio and arranged to publish electronically the definitive “node-positive” Oncotype paper at 5:30 PM CST, the moment that Dr Christos Sotiriou walked to the podium on the first day of the meeting to discuss the poster findings. This new SWOG analysis has the same message as the initial one: Patients with low and maybe intermediate Recurrence Score tumors don’t seem to benefit from chemotherapy. However, there is uniform support for a prospective trial very much like the one Dr Gianni described that will attempt to prospectively validate the clinical utility of the Recurrence Score for patients with node-positive tumors.

Our Patterns of Care surveys show that US-based oncologists are already using Oncotype DX for some patients with node-positive tumors, and this new data set is likely to increase reliance on this practice-changing assay. Hopefully, the test will help guide physicians to enroll their patients with node-positive, low Recurrence Score tumors on clinical trials of novel therapies that might lower the risk of disease progression. This shouldn’t be too difficult with the current PARP inhibitor mania and other promising approaches, such as the use of high-dose megestrol acetate to stimulate production of the NM23-H1 antimetastatic factor. One might also envision the utility of Oncotype DX for some older patients or those with comorbidities, with node-positive tumors and high Recurrence Scores who might otherwise be inclined to skip treatment but might reconsider with an assay predicting high efficacy.

What’s maybe even more important is what can be accomplished with an appropriate community-based research infrastructure and effective leadership as demonstrated by the Milan group and, for that matter, by the Austrians, whose zoledronic acid adjuvant study was among the most important new data sets in the field in recent years. Drawing from a smaller population than in the state of Florida, the Milan group believes it can complete what is most definitely a landmark study. To get results quicker, maybe the NSABP should consider joining in. It would be the perfect partnership, considering how these two groups and their founding fathers truly helped move the field forward for the benefit of patients.

Neil Love, MD
Research To Practice
Miami, Florida
Prognostic and Predictive Value of the 21-Gene Recurrence Score® for Women with Node-Positive Breast Cancer Receiving Chemotherapy

Presentation discussed in this issue


Slides from a journal article and transcribed comments from Joseph A Sparano, MD (1/20/10) at a closed roundtable meeting and a recent interview with Adam M Brufsky, MD, PhD (12/23/09)

---

**Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen-Receptor-Positive Breast Cancer on Chemotherapy: A Retrospective Analysis of a Randomised Trial**

**Albain KS et al.**

**Albain KS et al.**
San Antonio Breast Cancer Symposium 2009;Abstract 112.
Introduction

- A low 21-gene recurrence score (RS) in postmenopausal patients with ER-positive, node-negative breast cancer predicts a lack of benefit from the addition of chemotherapy to tamoxifen (T) treatment (JCO 2006;24:3726).
- The value of the 21-gene recurrence score assay in patients with ER-positive, node-positive breast cancer that are treated with T alone is unknown.
- **Current study objectives:**
  - Assess prognostic value of the 21-gene recurrence score in patients with node-positive breast cancer treated only with T.
  - Assess whether 21-gene recurrence assay allows for the prediction of a node-positive subset of patients who do not benefit from anthracycline-based chemotherapy.


SWOG-8814: Parent Trial Schema

**Eligibility (n=1,477)**
- Postmenopausal
- ER or PR positive
- Axillary lymph node positive

*CAF = Doxorubicin 30 mg/m² day 1, day 8
Cyclophosphamide 100 mg/m² PO days 1-14
5-FU 500 mg/m² day 1, day 8;
Cycle repeated q 28 days

* Excluded from analysis due to inferior efficacy

**Tamoxifen (T)**
- Tamoxifen 20 mg PO QD x 5 yrs

**CAF-T**
- CAF x 6 Cycles →
- T x 20 mg PO QD x 5 yrs

**CAFT**
- CAF x 6 Cycles
- Concurrent T 20 mg PO QD x 5 yrs

**SWOG-8814: Translational Study**

1,477 patients randomly assigned to trial

664 tumor samples available from central banking

601 samples analyzed by RT PCR: 148 T alone; 219 CAF → T; 234 CAFT

367 final samples for this analysis (Tamoxifen and CAF-T groups only; CAFT group excluded due to inferior efficacy)

Primary analysis: Cox regression model using continuous RS
Secondary analysis: RS categories, low (<18), intermediate (18-30) and high (≥31)


---

**Ten-Year Disease-Free Survival (DFS) and Overall Survival (OS) in Tamoxifen Alone Group**

<table>
<thead>
<tr>
<th>RS Group</th>
<th>10-year DFS</th>
<th>DFS p-value*</th>
<th>10-year OS</th>
<th>OS p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low (&lt;18)</td>
<td>60%</td>
<td></td>
<td>77%</td>
<td></td>
</tr>
<tr>
<td>Intermediate (18-30)</td>
<td>49%</td>
<td>0.017</td>
<td>68%</td>
<td>0.003</td>
</tr>
<tr>
<td>High (≥31)</td>
<td>43%</td>
<td></td>
<td>51%</td>
<td></td>
</tr>
</tbody>
</table>

*Log-rank p-value stratified according to the number of positive nodes (1-3 vs ≥4 positive nodes).

Hazard Ratio: Ten-Year DFS, T versus CAF-T Groups

<table>
<thead>
<tr>
<th>RS Group</th>
<th>HR (95% CI)</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low (&lt;18)</td>
<td>1.02 (0.54-1.93)</td>
<td>0.97</td>
</tr>
<tr>
<td>Intermediate (18-30)</td>
<td>0.72 (0.39-1.31)</td>
<td>0.48</td>
</tr>
<tr>
<td>High (≥31)</td>
<td>0.59 (0.35-1.01)</td>
<td>0.033</td>
</tr>
<tr>
<td>Entire RS sample</td>
<td>—</td>
<td>0.054</td>
</tr>
</tbody>
</table>

*Log-rank p-value stratified according to the number of positive nodes (1-3 vs ≥4 positive nodes); HR = hazard ratio.


Conclusions

- The RS is prognostic for patients with node-positive breast cancer treated with tamoxifen alone.
- A high RS score predicts an improved DFS in patients with node-positive breast cancer treated with anthracyline-based chemotherapy followed by tamoxifen compared to tamoxifen alone.
- A low RS score identifies women with node-positive breast cancer who may not benefit from the addition of anthracyline-based chemotherapy to tamoxifen treatment.

"Prospective studies with larger sample sizes are essential to establish who benefits most from modern endocrine therapy plus chemotherapy, and whether use of multigene assays affects survival."

- KS Albain

**DR SPARANO:** This is an important follow-up of a paper that’s already been presented previously in 2007. There are two principles to keep in mind when examining this paper.

The first is the notion of nodal status as a prognostic factor. Nodal status, unlike Recurrence Score (RS) or some of these other multigene factors, is really a time-dependent variable. Multigene profiles are generally static variables and represent a snapshot of the biology of the disease at that particular moment. The degree of nodal involvement is dependent upon not only the biology of the disease but also on how long the disease has been present. It is also likely a surrogate for the amount of micrometastatic disease present. That has been shown nicely in other work — that patients with node-positive disease have a higher disseminated tumor cell prevalence than patients with node-negative disease.

The second principle is that in the few trials that have examined how well multigene parameters correlate with clinical features, it seems that the two correlate very poorly with each other. What that indicates is that they’re really measuring different things.

The parent SWOG-8814 trial targeted postmenopausal women who had node-positive, ER-positive disease. They were randomly assigned to tamoxifen versus tamoxifen plus CAF chemotherapy, either concurrently or sequentially, followed by tamoxifen. This analysis was restricted to those who were assigned to tamoxifen alone versus CAF followed sequentially by tamoxifen, which was an arm that did better than the concurrent tamoxifen arm. They examined a subset of patients enrolled in the trial, about 40 percent of the parent trial, a relatively small sample size of 367 patients.

**DR BRUFSKY:** The RS was a greater predictor than anything else examined — greater than having one to three positive nodes, greater than having four positive nodes. That is the main finding of this paper. In the low-RS subset of women with node-positive disease, no matter how many positive nodes they have, patients are just not going to benefit from receiving chemotherapy, and these patients appear to obtain substantial benefit just from hormonal therapy.

**DR SPARANO:** The results were similar to what had been previously reported in the B-20 trial, which looked at patients with ER-positive, node-negative disease treated with tamoxifen or tamoxifen plus CMF. The benefit of chemotherapy seemed to be restricted to those who had a high RS. A statistically significant benefit was not seen in those who had a low RS or an intermediate RS, although in both studies there seemed to be a slight trend favoring the use of chemotherapy in that group.

**DR BRUFSKY:** The take-home message for me as an oncologist is that I am going to do this assay on women with node-positive breast cancer, at least postmenopausal women. The typical kind of woman who you’re going to see as a patient — around 65 to 70 years old with ER-positive breast cancer and two or three positive nodes — should have this assay done in my opinion. There are also the patients who are...
strongly averse to chemotherapy. If you perform the Oncotype DX® assay on these patients and they have a low RS of less than 18, you now have some data to support administering only endocrine therapy. The results of this study reinforce that.

**DR SPARANO:** I think this study provides reassurance that the RS can be potentially useful for patients who have node-positive disease, and it might be useful in selecting individuals who may not benefit from chemotherapy. We are talking about a small data set, however, and it would be reassuring to see more data.

Now that the approval for the Oncotype DX assay has been expanded to include patients who have node-positive disease, it makes me feel more comfortable about using the assay in older patients who have low-volume node-positive disease and using the assay as a means to spare administering chemotherapy to patients to whom I would have otherwise recommended chemotherapy.

**Editor’s Note:** As mentioned in the cover email, a new clinical trial from the Fondazione Michelangelo will prospectively assess the use of Oncotype DX in patients with node-positive and larger tumors.

*Dr Brufsky is Associate Professor of Medicine and Associate Division Chief of Hematology/Oncology at the University of Pittsburgh, Co-Director of the Comprehensive Breast Cancer Center and Associate Director for Clinical Investigation at the University of Pittsburgh Cancer Institute in Pittsburgh, Pennsylvania.*

*Dr Sparano is Professor of Medicine and Women’s Health at the Albert Einstein College of Medicine, Associate Chairman of the Department of Oncology at the Montefiore Medical Center and Director of the Breast Evaluation Center at the Montefiore-Einstein Cancer Center in Bronx, New York.*